KR100893977B1 - 이소티아졸 유도체의 제조 방법 - Google Patents
이소티아졸 유도체의 제조 방법 Download PDFInfo
- Publication number
- KR100893977B1 KR100893977B1 KR1020077004371A KR20077004371A KR100893977B1 KR 100893977 B1 KR100893977 B1 KR 100893977B1 KR 1020077004371 A KR1020077004371 A KR 1020077004371A KR 20077004371 A KR20077004371 A KR 20077004371A KR 100893977 B1 KR100893977 B1 KR 100893977B1
- Authority
- KR
- South Korea
- Prior art keywords
- benzyloxy
- carboxylic acid
- ureido
- isothiazole
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UWITWVXLWLBPCU-UHFFFAOYSA-N COC(c(c(O)n[s]1)c1S(C)(=O)=O)=O Chemical compound COC(c(c(O)n[s]1)c1S(C)(=O)=O)=O UWITWVXLWLBPCU-UHFFFAOYSA-N 0.000 description 1
- 0 COC(c(c(OC(*)=O)n[s]1)c1S(C)(=O)=O)=O Chemical compound COC(c(c(OC(*)=O)n[s]1)c1S(C)(=O)=O)=O 0.000 description 1
- SBKINGHNPUEFHX-UHFFFAOYSA-N COC(c(c(OC(OC)=O)n[s]1)c1S(C)(=O)=O)=O Chemical compound COC(c(c(OC(OC)=O)n[s]1)c1S(C)(=O)=O)=O SBKINGHNPUEFHX-UHFFFAOYSA-N 0.000 description 1
- RZJCAPLYUBBPPE-UHFFFAOYSA-N COC(c1c(SC)[s]nc1OC(OC)=O)=O Chemical compound COC(c1c(SC)[s]nc1OC(OC)=O)=O RZJCAPLYUBBPPE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60454204P | 2004-08-26 | 2004-08-26 | |
| US60/604,542 | 2004-08-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070070158A KR20070070158A (ko) | 2007-07-03 |
| KR100893977B1 true KR100893977B1 (ko) | 2009-04-20 |
Family
ID=36000502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077004371A Expired - Fee Related KR100893977B1 (ko) | 2004-08-26 | 2005-08-02 | 이소티아졸 유도체의 제조 방법 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8884025B2 (enExample) |
| EP (1) | EP1784183B1 (enExample) |
| JP (2) | JP5100390B2 (enExample) |
| KR (1) | KR100893977B1 (enExample) |
| CN (1) | CN101043888B (enExample) |
| AR (1) | AR050613A1 (enExample) |
| AT (1) | ATE542533T1 (enExample) |
| AU (1) | AU2005280451B2 (enExample) |
| BR (1) | BRPI0514667A (enExample) |
| CA (1) | CA2578023C (enExample) |
| DK (1) | DK1784183T3 (enExample) |
| ES (1) | ES2378994T3 (enExample) |
| IL (1) | IL181063A0 (enExample) |
| MX (1) | MX2007002246A (enExample) |
| NO (1) | NO20071319L (enExample) |
| PL (1) | PL1784183T3 (enExample) |
| PT (1) | PT1784183E (enExample) |
| RU (1) | RU2349588C2 (enExample) |
| TW (1) | TWI361688B (enExample) |
| WO (1) | WO2006026034A2 (enExample) |
| ZA (1) | ZA200701016B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007002246A (es) | 2004-08-26 | 2007-04-20 | Pfizer Prod Inc | Procedimientos para la preparacion de derivados de isotiazol. |
| ES2623652T3 (es) | 2011-12-28 | 2017-07-11 | Allergan, Inc. | Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa |
| CN103833665B (zh) * | 2014-02-24 | 2015-09-23 | 杰达维(上海)医药科技发展有限公司 | 一种新的合成异噻唑的方法 |
| US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
| US9403803B2 (en) | 2014-10-08 | 2016-08-02 | Allergan, Inc. | Indole-3-carboxamides as kinase inhibitors |
| US9359336B2 (en) | 2014-10-09 | 2016-06-07 | Allergan, Inc. | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors |
| US9371314B2 (en) | 2014-10-09 | 2016-06-21 | Allergan, Inc. | Pyridyl benzothiophenes as kinase inhibitors |
| KR20250121146A (ko) * | 2022-12-28 | 2025-08-11 | 비양 테라퓨틱스 컴퍼니 리미티드 | 단백질 티로신 키나제 억제제 및 이의 의약적 용도 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235764B1 (en) | 1998-06-04 | 2001-05-22 | Pfizer Inc. | Isothiazole derivatives useful as anticancer agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2408234A1 (de) * | 1974-02-21 | 1975-09-04 | Celamerck Gmbh & Co Kg | Isothiazolylharnstoffe |
| US4059433A (en) * | 1976-06-18 | 1977-11-22 | Fmc Corporation | 3-Alkoxyisothiazole derivatives as herbicides |
| IL72093A0 (en) * | 1983-06-20 | 1984-10-31 | Lilly Co Eli | N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| JP4511352B2 (ja) * | 2002-07-25 | 2010-07-28 | ファイザー・インク | 抗癌薬として有用なイソチアゾール誘導体 |
| US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
| MX2007002246A (es) | 2004-08-26 | 2007-04-20 | Pfizer Prod Inc | Procedimientos para la preparacion de derivados de isotiazol. |
-
2005
- 2005-08-02 MX MX2007002246A patent/MX2007002246A/es active IP Right Grant
- 2005-08-02 AT AT05778840T patent/ATE542533T1/de active
- 2005-08-02 ES ES05778840T patent/ES2378994T3/es not_active Expired - Lifetime
- 2005-08-02 AU AU2005280451A patent/AU2005280451B2/en not_active Ceased
- 2005-08-02 CN CN2005800284337A patent/CN101043888B/zh not_active Expired - Fee Related
- 2005-08-02 BR BRPI0514667-4A patent/BRPI0514667A/pt active Search and Examination
- 2005-08-02 US US11/574,046 patent/US8884025B2/en not_active Expired - Fee Related
- 2005-08-02 JP JP2007537876A patent/JP5100390B2/ja not_active Expired - Fee Related
- 2005-08-02 WO PCT/US2005/027398 patent/WO2006026034A2/en not_active Ceased
- 2005-08-02 CA CA2578023A patent/CA2578023C/en not_active Expired - Fee Related
- 2005-08-02 PT PT05778840T patent/PT1784183E/pt unknown
- 2005-08-02 EP EP05778840A patent/EP1784183B1/en not_active Expired - Lifetime
- 2005-08-02 RU RU2007106847/04A patent/RU2349588C2/ru not_active IP Right Cessation
- 2005-08-02 PL PL05778840T patent/PL1784183T3/pl unknown
- 2005-08-02 KR KR1020077004371A patent/KR100893977B1/ko not_active Expired - Fee Related
- 2005-08-02 DK DK05778840.8T patent/DK1784183T3/da active
- 2005-08-22 TW TW094128618A patent/TWI361688B/zh not_active IP Right Cessation
- 2005-08-23 AR ARP050103539A patent/AR050613A1/es not_active Application Discontinuation
-
2007
- 2007-01-30 IL IL181063A patent/IL181063A0/en unknown
- 2007-02-02 ZA ZA200701016A patent/ZA200701016B/xx unknown
- 2007-03-09 NO NO20071319A patent/NO20071319L/no not_active Application Discontinuation
-
2012
- 2012-03-30 JP JP2012079463A patent/JP5498524B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-10 US US14/537,093 patent/US9371298B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235764B1 (en) | 1998-06-04 | 2001-05-22 | Pfizer Inc. | Isothiazole derivatives useful as anticancer agents |
| KR20010052516A (ko) * | 1998-06-04 | 2001-06-25 | 데이비드 존 우드 | 항암제로 유용한 이소티아졸 유도체 |
| US6548526B2 (en) | 1998-06-04 | 2003-04-15 | Pfizer Inc | Isothiazole derivatives useful as anticancer agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5498524B2 (ja) | イソチアゾール誘導体の製造方法 | |
| US11001582B2 (en) | Solid state forms of Venetoclax and processes for preparation of Venetoclax | |
| JP5453437B2 (ja) | Cb2受容体を選択的に調節するスルホニル化合物 | |
| TW513418B (en) | Thiazole derivatives, their production and use | |
| BRPI0912878B1 (pt) | Compostos derivados de indazóis substituídos por fenila e benzodioxinila e composição farmacêutica que os compreende | |
| JP6523334B2 (ja) | 置換サイクロセリンの調製のための方法 | |
| JP2025513031A (ja) | オキサジアゾール化合物、それを含む医薬組成物及びその使用 | |
| HK1111359B (en) | Processes for the preparation of isothiazole derivatives | |
| KR20050017776A (ko) | 글리메피라이드의 제조방법 | |
| HK1154580B (en) | Benzodioxinyl substituted indazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20130325 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20140325 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20160325 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20170331 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20180503 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20200411 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200411 |